Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
$25.57
-2.7%
$23.83
$19.10
$29.55
$1.26B1.78395,316 shs562,596 shs
Cadre Holdings, Inc. stock logo
CDRE
Cadre
$33.75
-1.6%
$31.68
$27.07
$40.28
$1.39B1.3235,714 shs645,691 shs
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
$11.54
-1.8%
$11.00
$8.08
$18.23
$411.03M0.85491,225 shs1.05 million shs
NovoCure Limited stock logo
NVCR
NovoCure
$12.69
-2.4%
$12.70
$10.87
$34.13
$1.45B0.581.37 million shs2.17 million shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
-2.70%+0.24%+2.44%+20.50%+7.80%
Cadre Holdings, Inc. stock logo
CDRE
Cadre
-1.75%+4.11%+15.51%+2.59%-7.61%
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
-1.79%+6.46%+11.71%-16.68%+27.51%
NovoCure Limited stock logo
NVCR
NovoCure
-2.38%+4.44%+7.72%-23.97%-27.94%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
$25.57
-2.7%
$23.83
$19.10
$29.55
$1.26B1.78395,316 shs562,596 shs
Cadre Holdings, Inc. stock logo
CDRE
Cadre
$33.75
-1.6%
$31.68
$27.07
$40.28
$1.39B1.3235,714 shs645,691 shs
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
$11.54
-1.8%
$11.00
$8.08
$18.23
$411.03M0.85491,225 shs1.05 million shs
NovoCure Limited stock logo
NVCR
NovoCure
$12.69
-2.4%
$12.70
$10.87
$34.13
$1.45B0.581.37 million shs2.17 million shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
-2.70%+0.24%+2.44%+20.50%+7.80%
Cadre Holdings, Inc. stock logo
CDRE
Cadre
-1.75%+4.11%+15.51%+2.59%-7.61%
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
-1.79%+6.46%+11.71%-16.68%+27.51%
NovoCure Limited stock logo
NVCR
NovoCure
-2.38%+4.44%+7.72%-23.97%-27.94%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
3.13
Buy$31.2922.35% Upside
Cadre Holdings, Inc. stock logo
CDRE
Cadre
2.00
Hold$31.50-6.67% Downside
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
3.00
Buy$24.50112.31% Upside
NovoCure Limited stock logo
NVCR
NovoCure
2.57
Moderate Buy$28.79126.84% Upside

Current Analyst Ratings Breakdown

Latest DCTH, NVCR, CDRE, and BLFS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/13/2025
Cadre Holdings, Inc. stock logo
CDRE
Cadre
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeNeutralUnderperform$38.00 ➝ $26.00
8/11/2025
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
8/8/2025
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$30.00 ➝ $32.00
8/7/2025
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$29.00 ➝ $31.00
7/25/2025
NovoCure Limited stock logo
NVCR
NovoCure
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweightEqual Weight$40.00 ➝ $14.50
7/22/2025
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
Stephens
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$30.00
7/8/2025
NovoCure Limited stock logo
NVCR
NovoCure
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$30.00
6/27/2025
NovoCure Limited stock logo
NVCR
NovoCure
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$34.00
6/23/2025
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
Stephens
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$25.00
(Data available from 9/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
$82.25M14.89$0.12 per share214.51$7.52 per share3.40
Cadre Holdings, Inc. stock logo
CDRE
Cadre
$567.56M2.42$1.39 per share24.22$7.67 per share4.40
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
$37.21M10.85N/AN/A$2.15 per share5.37
NovoCure Limited stock logo
NVCR
NovoCure
$605.22M2.34N/AN/A$3.33 per share3.81
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
-$20.18M-$0.12N/AN/AN/A-5.39%0.16%0.14%11/11/2025 (Estimated)
Cadre Holdings, Inc. stock logo
CDRE
Cadre
$36.13M$0.9435.9024.821.266.65%12.08%5.60%11/5/2025 (Estimated)
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
-$26.39M$0.05230.80N/AN/A3.18%6.91%5.80%11/14/2025 (Estimated)
NovoCure Limited stock logo
NVCR
NovoCure
-$168.63M-$1.56N/AN/AN/A-27.13%-47.74%-13.79%10/29/2025 (Estimated)

Latest DCTH, NVCR, CDRE, and BLFS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
-$0.02-$0.33-$0.31-$0.33$23.71 million$25.42 million
8/6/2025Q2 2025
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
$0.02$0.07+$0.05$0.07$22.84 million$24.16 million
8/5/2025Q2 2025
Cadre Holdings, Inc. stock logo
CDRE
Cadre
$0.25$0.30+$0.05$0.30$153.23 million$157.11 million
7/24/2025Q2 2025
NovoCure Limited stock logo
NVCR
NovoCure
-$0.39-$0.36+$0.03-$0.36$153.87 million$158.80 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
N/AN/AN/AN/AN/A
Cadre Holdings, Inc. stock logo
CDRE
Cadre
$0.381.13%N/A40.43%2 Years
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
N/AN/AN/AN/AN/A
NovoCure Limited stock logo
NVCR
NovoCure
N/AN/AN/AN/AN/A

Latest DCTH, NVCR, CDRE, and BLFS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/22/2025
Cadre Holdings, Inc. stock logo
CDRE
Cadre
quarterly$0.09501.16%8/1/20258/1/20258/15/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
N/A
4.43
3.45
Cadre Holdings, Inc. stock logo
CDRE
Cadre
0.90
3.59
2.56
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
N/A
10.88
9.87
NovoCure Limited stock logo
NVCR
NovoCure
0.28
1.45
1.39

Institutional Ownership

CompanyInstitutional Ownership
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
93.24%
Cadre Holdings, Inc. stock logo
CDRE
Cadre
43.95%
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
61.12%
NovoCure Limited stock logo
NVCR
NovoCure
84.61%

Insider Ownership

CompanyInsider Ownership
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
2.20%
Cadre Holdings, Inc. stock logo
CDRE
Cadre
31.50%
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
17.40%
NovoCure Limited stock logo
NVCR
NovoCure
5.52%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
44047.90 million46.85 millionOptionable
Cadre Holdings, Inc. stock logo
CDRE
Cadre
2,28440.66 million27.86 millionOptionable
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
6034.98 million28.89 millionOptionable
NovoCure Limited stock logo
NVCR
NovoCure
1,488111.80 million105.63 millionOptionable

Recent News About These Companies

Strs Ohio Invests $759,000 in NovoCure Limited $NVCR
Novocure earns Japanese approval for tumor-treating fields
Insider Spends US$997k Buying More Shares In NovoCure

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioLife Solutions stock logo

BioLife Solutions NASDAQ:BLFS

$25.57 -0.71 (-2.70%)
Closing price 09/19/2025 04:00 PM Eastern
Extended Trading
$25.56 -0.01 (-0.04%)
As of 09/19/2025 04:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

Cadre stock logo

Cadre NYSE:CDRE

$33.75 -0.55 (-1.60%)
Closing price 09/19/2025 03:59 PM Eastern
Extended Trading
$33.76 +0.02 (+0.04%)
As of 09/19/2025 04:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cadre Holdings, Inc. manufactures and distributes safety that provides protection to users in hazardous or life-threatening situations in the United States and internationally. The company operates in two segments, Products and Distribution. It offers body armor product, such as concealable, corrections, and tactical armor under the Safariland and Protech Tactical brand names; survival suits, remotely operated vehicles, specialty tools, blast sensors, accessories, and vehicle blast attenuation seats for bomb safety technicians; bomb suits; duty gear, including belts and accessories; and other protective equipment comprising communications gear, forensic and investigation products, firearms cleaning solutions, and crowd control products. The company also offers third-party products, such as uniforms, optics, boots, firearms, and ammunition. It serves first responders, such as state and local law enforcement, fire and rescue, explosive ordnance disposal technicians, emergency medical technicians, fishing, and wildlife enforcement and departments of corrections, as well as federal agencies including the U.S. Department of State, U.S. Department of Defense, U.S. Department of Interior, U.S. Department of Justice, U.S. Department of Homeland Security, U.S. Department of Corrections, the Department of Energy, Los Alamos National Laboratories, Waste Isolation Plant, and various foreign government agencies. Cadre Holdings, Inc. was founded in 1964 and is headquartered in Jacksonville, Florida.

Delcath Systems stock logo

Delcath Systems NASDAQ:DCTH

$11.54 -0.21 (-1.79%)
Closing price 09/19/2025 04:00 PM Eastern
Extended Trading
$11.30 -0.24 (-2.08%)
As of 09/19/2025 05:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

NovoCure stock logo

NovoCure NASDAQ:NVCR

$12.69 -0.31 (-2.38%)
Closing price 09/19/2025 04:00 PM Eastern
Extended Trading
$12.96 +0.27 (+2.13%)
As of 09/19/2025 07:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.